FDA 규제 화합물
이 화합물은 FDA 승인 또는 규제 대상입니다. 유효한 처방 없이 구매하는 것은 연방법 위반일 수 있습니다. 지역 법규를 확인하세요.
Semaglutide
Ozempic / Wegovy / Rybelsus
Semaglutide is an FDA-approved GLP-1 receptor agonist originally developed by Novo Nordisk for type 2 diabetes (Ozempic, Rybelsus) and later approved for chronic weight management (Wegovy). It is a 31-amino acid peptide analog of human GLP-1 with a half-life of approximately 7 days, enabling once-weekly dosing. It has become one of the most commercially successful peptide drugs in history, with combined annual revenues exceeding $20 billion.
작용 메커니즘
GLP-1 receptor agonist that mimics incretin hormones. Enhances insulin secretion in a glucose-dependent manner, suppresses glucagon release, and slows gastric emptying. Centrally reduces appetite through hypothalamic signaling.
연구 프로토콜
연구 용도만 사용 가능. 의학적 조언은 아닙니다.
Typical research protocols use 0.25mg weekly for 4 weeks, escalating to 0.5mg weekly, then 1mg weekly. Maximum studied dose is 2.4mg weekly for weight management.
연구 노트
Clinical Research Status
FDA-approved for type 2 diabetes (Ozempic 2017, Rybelsus 2019) and obesity (Wegovy 2021). Ongoing Phase 3 trials for NASH/MASH (liver disease), heart failure with preserved ejection fraction, Alzheimer's disease, and substance use disorders. SELECT trial demonstrated 20% cardiovascular risk reduction in overweight patients.
Key Published Findings
STEP trials demonstrated 15-17% average body weight loss over 68 weeks at 2.4mg weekly dose. SUSTAIN trials showed HbA1c reductions of 1.5-1.8% in type 2 diabetes. PIONEER trials established efficacy of oral formulation. FLOW trial showed 24% reduction in kidney disease progression. STEP HFpEF trial showed significant improvement in heart failure symptoms and physical limitations.
Safety Profile
Most common side effects are gastrointestinal: nausea (40-44%), diarrhea (30%), vomiting (24%), constipation (24%). These typically diminish with dose titration. Black box warning for thyroid C-cell tumors (observed in rodents, not confirmed in humans). Reports of pancreatitis, gallbladder events, and retinopathy complications. Post-marketing reports of suicidal ideation under investigation.
Drug Interactions & Contraindications
Contraindicated in patients with personal/family history of medullary thyroid carcinoma or MEN2 syndrome. Delays gastric emptying, which may affect absorption of other oral medications. Caution with insulin or sulfonylureas (increased hypoglycemia risk). Not recommended during pregnancy or breastfeeding.
Comparison to Related Compounds
More potent and longer-acting than liraglutide (Victoza/Saxenda). Tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 agonist showing slightly greater weight loss (up to 22.5% in SURMOUNT trials). Retatrutide (triple agonist) in Phase 3 trials shows even greater efficacy. CagriSema (semaglutide + cagrilintide) in Phase 3 trials combines GLP-1 and amylin pathways.
Community Observations
Extreme demand has led to widespread shortages and compounding pharmacy versions of varying quality. Counterfeit products are a significant concern. Users commonly report dramatic appetite suppression, food noise reduction, and altered relationship with alcohol. Muscle loss during weight loss is a frequently discussed concern — resistance training and adequate protein intake are widely recommended.
반감기
~7 days
재조성
Bacteriostatic water (BAC)
보관
건조한 상태
Room temperature up to 36 months. Protect from light.
재조성된 상태
Refrigerate 2-8C. Use within 56 days.
미국 법적 상태
또는 알려진 이름으로
최신 연구
Highlighting the efficacy and importance of continued GLP-1 receptor agonist therapy, specifically semaglutide, in maintaining weight loss for patients with obesity or overweight.
Highlighting the differential risk profiles of various GLP-1 receptor agonists for gastrointestinal adverse events based on real-world data, emphasizing implications for clinical practice.
Highlighting the comparative effectiveness and patient outcomes between once-weekly semaglutide and daily liraglutide for weight management in non-diabetic obese patients.
자주 묻는 질문
Semaglutide란 무엇인가요?
Semaglutide is an FDA-approved GLP-1 receptor agonist originally developed by Novo Nordisk for type 2 diabetes (Ozempic, Rybelsus) and later approved for chronic weight management (Wegovy). It is a 31-amino acid peptide analog of human GLP-1 with a half-life of approximately 7 days, enabling once-weekly dosing. It has become one of the most commercially successful peptide drugs in history, with combined annual revenues exceeding $20 billion.
Semaglutide는 어떻게 작용하나요?
GLP-1 receptor agonist that mimics incretin hormones. Enhances insulin secretion in a glucose-dependent manner, suppresses glucagon release, and slows gastric emptying. Centrally reduces appetite through hypothalamic signaling.
Semaglutide의 미국 규제 현황은 어떤가요?
FDA-approved (Rx only)
Semaglutide의 반감기는 얼마인가요?
~7 days
Semaglutide의 다른 이름은 무엇인가요?
Ozempic, Wegovy, Rybelsus
Peptide Contacts는 정보 제공을 위해 연구 기반 요약을 제공합니다. 우리는 공급업체 문서를 호스팅, 배포하거나 지지하지 않습니다. 모든 테스트 보고서, GMP 인증서 및 공급업체 통신은 구매자는 직접 요청하고 확인해야 합니다. 이 플랫폼에서 제공되는 어떠한 정보도 법적, 의학적 또는 전문적인 조언을 대체하지 않습니다. 사용자는 모든 관련 지역법, 주법 및 연방법에 부합하기 위해 공급업체 자격 증명을 검증하고 구매하기 전에 준수해야 합니다. 이 플랫폼의 사용은 이러한 책임을 완전히 지닌 것으로 간주됩니다.
전체 공지사항 읽기